参考文献

参考文献

[1]ARROYO J D, et al. Argonaute 2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma[J]. Proc Natl Acad Sci USA, 2011.

[2]BOERI M, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomograp detected lung cancer[J]. Proc Natl Acad Sci USA, 2011.

[3]CHEN Y, et al. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy[J]. Mol Ther, 2010.

[4]CHU H, et al. Hsa-miR-196a2 Rs11614913 polymorphism contributes to cancer susceptibility: evidence from 15 case-control studies[J]. PLoS One, 2011.

[5]CLARK M B, et al. Long noncoding RNAs in cell biology[J]. Semin Cell Dev Biol, 2011.

[6]GEE H E, et al. 'The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis[J]. Br J Cancer, 2011.

[7]GIBB E A, et al. The functional role of long non-coding RNA in human carcinomas[J]. Mol Cancer, 2011.

[8]ROSENTHAL J. Market watch: upcoming market catalysts in Q4 2010[J]. Nat Rev Drug Discov, 2010.

[9]HUNTER M P, et al. Detection of microRNA expression in human peripheral blood microvesicles[J]. PLoS One, 2008.

[10]RUVKUN G. Molecular biology. Glimpses of a tiny RNA world[J]. Science, 2001.

[11]RAGGO C, et al. Novel cellular genes essential for transformation of endothelial cells by Kaposi’s sarcoma-associated herpesvirus[J]. Cancer Res, 2005.

[12]KHAITAN Dr J, et al. The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion[J]. Cancer Res, 2011.

[13]MCDONALD J S, et aI. Analysis of circulating microRNA: preanalytical and analytical challenges[J]. Clin Chem, 2011.

[14]GILAD S, et al. Serum microRNAs are promising novel biomarkers[J]. PLoS One, 2008.

[15]PASQUINELLI A E, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA[J]. Nature, 2000.

[16]LIM L P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs[J]. Nature, 2005.

[17]CROCE C M. Causes and consequences of microRNA dysregulation in cancer[J]. Nat Rev Genet, 2009.

[18]IORIO M V, et al. Causes and consequences of microRNA dysregulation[J]. Cancer J, 2012.

[19]FLYNT A S, LAI E C. Biological principles of microRNA-mediated regulation: shared themes amid diversity[J]. Nat Rev Genet, 2008.

[20]WU L, et al. MicroRNAs direct rapid deadenylation of mRNA[J]. Proc Natl Acad Sci USA, 2006.

[21]OROM U A, et al. MicroRNA-l0a binds the 5’UTR of ribosomal protein mRNAs and enhances their translation[J]. Mol Cell, 2008.

[22]TANG F, et al. 220-plex microRNA expression profile of a single cell[J]. Nat Protoc, 200.

[23]TANG F, et al. MicroRNA expression profiling of single whole embryonic stem cells [J]. Nucleic Acids Res, 2006.

[24]GALLARDO E, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer[J]. Carcinogenesis, 2009.

[25]JI A, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells[J]. Hepatology, 2009.

[26]VINALL R, et al. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status[J]. Int J Cancer, 2012.

[27]YANG X, et al. miR-449a and miR-449b are direct transcriptional targets of E2F 1 and negatively regulate pRb-E2F 1 activity through a feedback loop by targeting CDK6 and CDC25A [J]. Genes Dev, 2009.

[28]YANG X, FENG M, JIANG X, et al. miR-449a and miR-449b are direct transcriptional targets of E2F l and negatively regulate pRb-E2F 1 activity through a feedback loop by targeting CDK6 and CDC25A[J]. Genes Dev, 2009.

[29]JEON H S, et al. Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer[J]. Lung Cancer, 2012.

[30]TRANG P, et al. Regression of marine lung tumors by the let-7 microRNA [J].Oncogene, 2010.

[31]UEDA T, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis[J]. Lancet Oncol, 2010.

[32]Lu J E A, et al. MicroRNA expression profiles classify human cancers[J]. Nature, 2005.

[33]CALIN G A, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia[J]. Proc Natl Acad Sci USA, 2002.

[34]WSZOLEK M F, et al. A MicroRNA expression profile defining the invasive bladder tumorphenotype[J]. Urol Oncol, 2011.

[35]GILAD S, et al. Serum microRNAs are promising novel biomarkers[J]. PLoS One, 2008.

[36]PUERTA-GIL A Y, et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer[J]. Am J Pathol, 2012.

[37]HANKE M, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer[J]. Urol Oncol, 2010.

[38]FENDLER A M, et al. MicroRNAs as regulators of signal transduction in urological tumors[J]. Clin Chem, 2011.

[39]SAITO Y, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells[J]. Cancer Cell, 2006.

[40]LIU Y, et al. Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells[J]. PLoS One, 2012.

[41]NOGUCHI S, et al. Replacement treatment with microRNA-143 and microRNA-145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/ Akt and MAPK signaling pathways[J]. Cancer Lett, 2013.